LNTH241018C55000
- 13.50
- 0.000.00%
Lantheus Newsroom
Truist Financial Maintains Lantheus(LNTH.US) With Buy Rating, Announces Target Price $135
JonesTrading Maintains Lantheus(LNTH.US) With Buy Rating, Maintains Target Price $137
Buy Rating Reaffirmed for Lantheus Holdings Amid Promising PNT2002 Trial Results
TD Cowen Maintains Lantheus(LNTH.US) With Buy Rating, Maintains Target Price $145
Truist Financial Maintains Lantheus(LNTH.US) With Buy Rating
Truist Financial Issues a Buy Rating on Lantheus (LNTH)
Redburn Atlantic Initiates Lantheus(LNTH.US) With Buy Rating, Announces Target Price $175
Strong Outlook for Lantheus: Buy Rating Amid Positive CMS Rule Changes and Promising Alzheimer's PET Agents
Analysts' Opinions Are Mixed on These Healthcare Stocks: Adaptimmune Therapeutics (ADAP), Lantheus (LNTH) and Vertex Pharmaceuticals (VRTX)
Lantheus: Strong Buy Rating on Robust Financials and Strategic Growth Prospects
JonesTrading Maintains Lantheus(LNTH.US) With Buy Rating, Maintains Target Price $137
Lantheus Holdings: A Strong Buy on Robust Q2 Performance and Strategic Growth Investments
Lantheus Holdings Price Target Cut to $135.00/Share From $141.00 by Truist Securities
Lantheus Holdings Analyst Ratings
Truist Financial Keeps Their Buy Rating on Lantheus (LNTH)
Truist Financial Maintains Lantheus(LNTH.US) With Buy Rating
JMP Securities Maintains Lantheus(LNTH.US) With Buy Rating, Cuts Target Price to $125
Lantheus Holdings: A Strong Buy on Robust Revenue Growth and Promising Pipeline
TD Cowen Maintains Lantheus(LNTH.US) With Buy Rating, Maintains Target Price $145
Strong Performance and Growth Prospects Justify Buy Rating for Lantheus